SLAM family member 8 is expressed in and enhances the growth of anaplastic large cell lymphoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 02 2020
13 02 2020
Historique:
received:
06
12
2018
accepted:
30
01
2020
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Signaling lymphocytic activation molecule family member 8 (SLAMF8) / B-lymphocyte activator macrophage expressed/CD353 is a member of the CD2 family. SLAMF8 suppresses macrophage function but enhances the growth of neoplastic mast cells via SHP-2. In this study, we found that some anaplastic large cell lymphoma (ALCL) samples were immunohistochemically positive for SLAMF8. However, we found no significant differences between SLAMF8-positive and SLAMF8-negative ALCL samples with respect to age, gender, site, or prognosis. We also identified SLAMF8 expression in ALCL cell lines, Karpas299, and SU-DHL-1. SLAMF8 knockdown decreased the activation of SHP-2 and the growth of these cell lines, and increased the apoptosis of these cell lines. In addition, we observed the interaction between SLAMF8 and SHP-2 in these cell lines using the DuoLink in situ kit. Taken together, these results suggest that SLAMF8 may enhance the growth of ALCL via SHP-2 interaction.
Identifiants
pubmed: 32054954
doi: 10.1038/s41598-020-59530-1
pii: 10.1038/s41598-020-59530-1
pmc: PMC7018816
doi:
Substances chimiques
SLAMF8 protein, human
0
Signaling Lymphocytic Activation Molecule Family
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2505Références
Wu, N. & Veillette, A. SLAM family receptors in normal immunity and immune pathologies. Curr. Opin. Immunol. 38, 45–51 (2016).
doi: 10.1016/j.coi.2015.11.003
Ma, C. S., Nichols, K. E. & Tangye, S. G. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu. Rev. Immunol. 25, 337–79 (2007).
doi: 10.1146/annurev.immunol.25.022106.141651
Orentas, R. J. et al. Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol. 2, 194 (2012).
pubmed: 23251904
pmcid: 3523547
Zhang, Q. et al. SLAMF8, a novel biomarker for personalized immune checkpoint blockade therapy in gastrointestinal cancer. J. Clin. Oncol. in press.
Kingsbury, G. A. et al. Cloning, expression, and function of BLAME, a novel member of the CD2 family. J. Immunol. 166, 5675–80 (2001).
doi: 10.4049/jimmunol.166.9.5675
Wang, G. et al. Cutting edge: Slamf8 is a negative regulator of Nox2 activity in macrophages. J. Immunol. 188, 5829–32 (2012).
doi: 10.4049/jimmunol.1102620
Sugimoto, A. et al. SLAM family member 8 is involved in oncogenic KIT-mediated signaling in human mastocytosis. Exp. Dermatol. 27, 641–6 (2018).
doi: 10.1111/exd.13523
Xing, X. & Feldman, A. L. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv. Anat. Pathol. 22, 29–49 (2015).
doi: 10.1097/PAP.0000000000000047
Epstein, A. L. & Kaplan, H. S. Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas. Cancer. 34, 1851–72 (1974).
doi: 10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4
Fischer, P. et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin’s lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 72, 234–40 (1988).
doi: 10.1182/blood.V72.1.234.234
Christensen, J. G. et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314–22 (2007).
doi: 10.1158/1535-7163.MCT-07-0365
Voena, C. et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 67, 4278–86 (2007).
doi: 10.1158/0008-5472.CAN-06-4350
Hellmuth, K. et al. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl. Acad. Sci. USA 105, 7275–80 (2008).
doi: 10.1073/pnas.0710468105
Söderberg, O. et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods. 3, 995–1000 (2006).
doi: 10.1038/nmeth947
Morra, M. et al. Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J. 20, 5840–52 (2001).
doi: 10.1093/emboj/20.21.5840
Álvarez-Errico, D. et al. CD84 negatively regulates IgE high-affinity receptor signaling in human mast cells. J. Immunol. 187, 5577–86 (2011).
doi: 10.4049/jimmunol.1101626
Sharma, N. et al. Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice. Oncotarget. 5, 6130–41 (2014).
Khoury, J. D. et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin. Cancer Res. 9, 3692–9 (2003).
pubmed: 14506160